(Image: Dr Andrew Nash)
On behalf of Burnet Institute, board chair Mary Padbury is pleased to announce the appointment of Dr Andrew Nash BSc (Hons) PhD FSTE to its Board of Directors.
Dr Nash brings more than 36 years’ experience in management, leadership, biomedical research, product development, research commercialisation, partnerships and licensing, and a deep understanding of how scientific discoveries can be transformed into real-world health solutions.
Dr Nash was most recently the Chief Scientific Officer at CSL Limited, leading a global team of more than 400 scientists across Australia, Germany, Switzerland and the United States. Under his leadership, new compounds progressed into clinical studies for multiple diseases, including rheumatoid arthritis, kidney disease and acute amyloid leukaemia, driven by platforms including mRNA.
Ms Padbury said Dr Nash would be a tremendous addition to the board.
“Dr Nash’s career bridges science, strategy and impact,” she said.
“He brings a powerful combination of scientific depth and commercial acumen that will further strengthen the Institute’s governance and effective focus on its health equity purpose.”
Dr Nash completed his PhD in Immunology at the University of Melbourne before leading a research group in cytokine biology at the Centre for Animal Biotechnology in the University’s veterinary science faculty. In 1996, he joined Zenyth Therapeutics (then AMRAD Corporation), where he held several leadership roles, including Chief Scientific Officer and Chief Executive Officer prior to its acquisition by CSL in 2006. During this time, he was instrumental in building research pipelines and securing major licensing agreements.
Throughout his career, Dr Nash has championed the translation of research into impact —building the partnerships, capability and infrastructure needed to bring discoveries to fruition. His experience across the discovery to impact continuum will add a valuable dimension to Burnet, to assist in transforming health outcomes through science, innovation and collaboration.
Read more about the Burnet Board of Directors.